A PHASE 3B STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DIFFERENT RETATRUTIDE DOSE ESCALATION SCHEMES IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND TRIAL (TRIUMPH-9)
- Registry ID
- J1I-MC-GZQL
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2026-02-19
- Last update
- 2025-12-10
Conditions
- OBESITY
- OVERWEIGHT/OBESITY
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY {VESPER 6)
- A PHASE II, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, 42-WEEK DOSE-FINDING TRIAL FOR BI 3034701 ADMINISTERED SUBCUTANEOUSLY COMPARED TO PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT
- A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ALN-6222 IN ADULT PARTICIPANTS WITH OBESITY
- A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF ELECOGLIPRON IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH OR WITHOUT TYPE 2 DIABETES MELLITUS (EMBOLD)
- A CLINICAL STUDY TO COMPARE EFFICACY AND SAFETY OF TWO DIFFERENT DOSES OF CAGRISEMA AND SEMAGLUTIDE IN PARTICIPANTS WITH OBESITY WITH OR WITHOUT TYPE 2 DIABETES
- EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
View on source registry